- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06308055
Abiomed Impella RT-DAQ - Observational Study
Abiomed IMPELLA-RT-DAQ - Impella Real Time Data AcQuisition
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Kirstin Starke
- Phone Number: +49 241 8860
- Email: kstarke@abiomed.com
Study Contact Backup
- Name: Andreas Goetzenich, MD, PhD, MBA, FAHA, FESC
- Phone Number: +49 241 8860
- Email: agoetzenich@abiomed.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Patients requiring cardiac Impella pump-support and intensive care therapy including cardiac output monitoring, eg. by pulmonary artery catheter at some point of therapy.
Initially, a collection of 250 patient days is aimed for. It is expected that each patient will be monitored by PAC for at least 48 hours, thus approximately 125 patients will be needed to achieve study objectives.
Description
Inclusion Criteria:
- Ongoing or planned intensive care management with Impella support
Presence or planned placement of a cardiac output measurement
- Preferentially pulmonary catheter (including cardiac output (CO) preferred as continuous measurement)
- Other means of discontinuous CO measurement incl. echocardiography, other thermodilution methods
Exclusion Criteria:
- Age < 18 years
- Pregnancy
- Anticipated support duration <24 h
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Collection of hemodynamic parameters (Cardiac Output in l/min)
Time Frame: From Impella insertion unitl Impella support is permanently weaned, on average 2 days
|
Synchronous data acquisition of the Impella system parameters (pressure measurement, motor current, operating data) and the monitoring system (Philipps IntelliVue) using a network module (HighDim) that is connected by either a wired or wireless access.
|
From Impella insertion unitl Impella support is permanently weaned, on average 2 days
|
Collection of hemodynamic parameters (Blood Pressure in mmHg, Pulmonary Artery Pressure in mmHg, Central Venous Pressure in mmHg, Pulmonary Capillary Wedge Pressure in mmHg)
Time Frame: From Impella insertion unitl Impella support is permanently weaned, on average 2 days
|
Synchronous data acquisition of the Impella system parameters (pressure measurement, motor current, operating data) and the monitoring system (Philipps IntelliVue) using a network module (HighDim) that is connected by either a wired or wireless access.
|
From Impella insertion unitl Impella support is permanently weaned, on average 2 days
|
Collection of hemodynamic parameters (Mixed Venous Saturation in %)
Time Frame: From Impella insertion unitl Impella support is permanently weaned, on average 2 days
|
Synchronous data acquisition of the Impella system parameters (pressure measurement, motor current, operating data) and the monitoring system (Philipps IntelliVue) using a network module (HighDim) that is connected by either a wired or wireless access.
|
From Impella insertion unitl Impella support is permanently weaned, on average 2 days
|
Collection of hemodynamic parameters (Pulmonary Vascular Resistance in In dynes/sec/cm-5 )
Time Frame: From Impella insertion unitl Impella support is permanently weaned, on average 2 days
|
Synchronous data acquisition of the Impella system parameters (pressure measurement, motor current, operating data) and the monitoring system (Philipps IntelliVue) using a network module (HighDim) that is connected by either a wired or wireless access.
|
From Impella insertion unitl Impella support is permanently weaned, on average 2 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rate of Patient Survival
Time Frame: Once the Impella support is permanently weaned, on average 2 days
|
Once the Impella support is permanently weaned, on average 2 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Alexander Kersten, MD, Uniklinik RWTH Aachen, Klinik für Kardiologie, Angiologie und Internistische Intensivmedizin
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022-R01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiogenic Shock
-
University Hospital, MontpellierRecruiting
-
Odense University HospitalCharite University, Berlin, Germany; Hannover Medical School; Aarhus University... and other collaboratorsCompletedAcute Myocardial Infarction | Cardiogenic Shock AcuteGermany, Denmark, United Kingdom
-
Assaf-Harofeh Medical CenterUnknownMyocardial Infarction Complicated With Cardiogenic ShockIsrael
-
Hospices Civils de LyonCompleted
-
Wentworth Area Health ServicesAbbottUnknown
-
Universität MünsterNot yet recruiting
-
University of UtahUniversity of MinnesotaRecruiting
-
Windtree TherapeuticsMomentum Research, Inc.Not yet recruiting
-
Australian and New Zealand Intensive Care Research...Not yet recruitingCardiogenic Shock
-
Yonsei UniversityRecruitingCardiogenic ShockKorea, Republic of
Clinical Trials on Data Acquisition
-
University Hospital, Basel, SwitzerlandRecruitingFrailty | Distress, EmotionalSwitzerland
-
Emanuela ValsangiacomoCompletedIndication, Unlabeled
-
GlaxoSmithKlineCompletedNeoplasms, Urinary BladderBelgium
-
GlaxoSmithKlineCompletedPathologically Proven Stage I, II and III Non-Small Cell Lung Cancer (NSCLC)Singapore, Korea, Republic of
-
Samsung Medical CenterCompletedStrokeKorea, Republic of
-
IRCCS Fondazione Stella MarisUniversity of Pisa; The University of Queensland; University of Castilla-La Mancha and other collaboratorsNot yet recruitingUnilateral Cerebral PalsyItaly, Spain
-
Consolidated Research, Inc.Recruiting
-
University of WashingtonNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Not yet recruitingNephrolithiasis | Urolithiasis | Kidney Stones | Ureter StonesUnited States
-
Samsung Medical CenterCompleted
-
Semmelweis UniversityCompletedIdentity, Body | Palate; DeformityHungary